LabGenius
Uses machine learning and robotic automation to discover novel protein therapeutics.
What they do
LabGenius operates an automated, closed-loop discovery platform that designs, conducts, and learns from its own wet-lab experiments. Pharmaceutical partners use this system to optimize protein-based therapeutics, specifically engineered antibodies for oncology and inflammatory diseases.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Service
- Stage
- Series B
- Headquarters
- London, UK
- Region
- Europe
- Founded
- 2012
- Total funding
- $43M raised
Notable investors: Atomico, Lux Capital, Obvious Ventures, Octopus Ventures.